Last updated on August 2009

The New Strategy for Pharmacological Treatment in People With Schizophrenia

Brief description of study

Switching from Risperidone to Aripiprazole in early stage of pharmacotherapy will demonstrate the same efficacy as compared to risperidone continuation treatment in the treatment of schizophrenia.

Detailed Study Description

It has been thought that D2 Blocking agent is necessary in acute as well as maintenance phase of pharmacological treatment of patients with schizophrenia. However, this classical strategy produces long term adverse events of drug such as TD, osteoporosis and some metabolic syndrome. To overcome these adverse events, new strategy for pharmacological treatment is needed.

Clinical Study Identifier: NCT00352339

Find a site near you

Start Over

Dongrae Hospital

Busan, Korea, Republic of
  Connect »